Since collecting blood-based biomarkers is more practical and desirable for extensive clinical trials as compared to CSF-based biomarkers, numerous studies have analyzed serum NfL levels in the context of different neurological disorders such as multiple sclerosis9,10, dementia11, progressive supranuclear palsy12, traumatic brain injury (TBI)13, Parkinson’s disease14, Alzheimer’s disease15, and Huntington’s disease16. Here, NEFL is linked to nervous system disorder.